All In Biotech

Drug Trial Radar · NCT03546907

Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of SAR440340, in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Last checked: Nov 19, 2026Latest source record: Nov 22, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 343 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

343

Actual

Start

Jul 16, 2018

Primary completion

Oct 3, 2019

Study completion Feb 21, 2020

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Regeneron Pharmaceuticals
First posted
Jun 6, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To investigate effects of SAR440340 (anti-interleukin-33 \[IL-33\] monoclonal antibody \[mAb\]) compared with placebo, on the annualized rate of moderate-to-severe acute exacerbations of COPD (AECOPD) over up to 52 weeks of treatment. * Moderate exacerbations were recorded by the Investigator and defined as AECOPD that require either systemic corticosteroids (such as intramuscular, intravenous or oral) and/or antibiotics. * Severe exacerbations were recorded by the Investigator and defined as AECOPD requiring hospitalization, emergency medical care visit or resulting in death. Secondary Objectives: To investigate effects of SAR440340 compared with placebo, on improving respiratory function, as assessed by pre-bronchodilator forced exploratory volume in 1 second (FEV1). To evaluate effects of SAR440340 compared with placebo, on post-bronchodilator FEV1. To evaluate effects of SAR440340 compared with placebo, on duration from baseline to first moderate or severe AECOPD event. To evaluate effects of SAR440340 compared with placebo, on safety and tolerability.

Conditions

  • Chronic Obstructive Pulmonary Disease

Interventions

  • SAR440340Drug

    Pharmaceutical form: Solution for injection; Route of administration: SC

  • PlaceboDrug

    Pharmaceutical form: Solution for injection; Route of administration: SC

  • Any Inhaled Corticosteroids as prescribed by treating physician as standard of careDrug

    Pharmaceutical form: Aerosol or Dry Powder inhaler Route of administration: Inhaled

  • Any Long Acting Beta Agonist as prescribed by treating physician as standard of careDrug

    Pharmaceutical form: Aerosol or Dry Powder inhaler; Route of administration: Inhaled

  • Any Long Acting Muscarinic Agonist as prescribed by treating physician as standard of careDrug

    Pharmaceutical form: Aerosol or Dry Powder inhaler; Route of administration: Inhaled

  • Any short-acting β agonist as prescribed by treating physician as standard of careDrug

    Pharmaceutical form: Aerosol or Dry Powder inhaler; Route of administration: inhaled

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Rate of Moderate to Severe Acute Exacerbation Events in Chronic Obstructive Pulmonary Disease (AECOPD) ParticipantsTime frame: From Baseline up to Week 52

Locations

83 sites in 10 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 8400002

    Los Angeles, California

  • Investigational Site Number 8400003

    Riverside, California

  • Investigational Site Number 8400006

    Rolling Hills Estates, California

  • Investigational Site Number 8400015

    Westminster, California

  • Investigational Site Number 8400013

    Jacksonville, Florida

  • Investigational Site Number 8400012

    Columbia, Maryland

  • Investigational Site Number 8400016

    North Dartmouth, Massachusetts

  • Investigational Site Number 8400020

    South Dartmouth, Massachusetts

  • Investigational Site Number 8400011

    Minneapolis, Minnesota

  • Investigational Site Number 8400005

    Jamaica, New York

  • Investigational Site Number 8400019

    Chapel Hill, North Carolina

  • Investigational Site Number 8400004

    Raleigh, North Carolina

  • Investigational Site Number 8400001

    Medford, Oregon

  • Investigational Site Number 8400009

    Philadelphia, Pennsylvania

  • Investigational Site Number 8400007

    Plano, Texas

  • Investigational Site Number 8400008

    Greenfield, Wisconsin

  • Investigational Site Number 0320001

    Buenos Aires, Argentina

  • Investigational Site Number 0320005

    Caba, Argentina

  • Investigational Site Number 0320002

    Caba, Argentina

  • Investigational Site Number 0320004

    Caba, Argentina

  • Investigational Site Number 0320006

    Quilmes, Argentina

  • Investigational Site Number 0320003

    Rosario, Argentina

  • Investigational Site Number 0360005

    Bedford Park, Australia

  • Investigational Site Number 0360002

    Chermside, Australia

  • Investigational Site Number 0360004

    Clayton, Australia

  • Investigational Site Number 0360003

    Frankston, Australia

  • Investigational Site Number 0360006

    Kent Town, Australia

  • Investigational Site Number 0360001

    Murdoch, Australia

  • Investigational Site Number 1240002

    Burlington, Canada

  • Investigational Site Number 1240009

    Hamilton, Canada

  • Investigational Site Number 1240003

    Montreal, Canada

  • Investigational Site Number 1240001

    Montreal, Canada

  • Investigational Site Number 1240005

    Québec, Canada

  • Investigational Site Number 1240006

    Saint-Charles-Borromée, Canada

  • Investigational Site Number 1240008

    Trois-Rivières, Canada

  • Investigational Site Number 1240007

    Vancouver, Canada

  • Investigational Site Number 1240004

    Victoriaville, Canada

  • Investigational Site Number 1520002

    Quillota, Chile

  • Investigational Site Number 1520001

    Santiago, Chile

  • Investigational Site Number 1520007

    Santiago, Chile

Showing 40 of 83 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.